A Study of JNJ-77242113 in Participants With Moderate-to-severe Plaque Psoriasis

NCT05223868 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

255

Enrollment

INDUSTRY

Sponsor class

Conditions

Plaque Psoriasis

Interventions

DRUG: JNJ-77242113
DRUG: Placebo

Sponsor

Janssen Research & Development, LLC